Tempus AI reported strong Q3 2024 results with revenue up 33% YoY to $180.9M. Genomics revenue grew 20.3% to $116.4M, while data and services revenue surged 64.4% to $64.5M. The company's net loss widened to $75.8M from $53.4M YoY, including $22.2M in stock compensation expenses.Tempus announced the acquisition of Ambry Genetics for $600M, comprising $375M in cash and $225M in shares. Ambry is expected to generate over $300M in revenue and $40M+ in EBITDA in 2024. The deal aims to expand Tempus' testing capabilities in hereditary cancer screening and new disease categories.For full-year 2024, Tempus maintains its revenue guidance of approximately $700M, representing 32% YoY growth. The company expects adjusted EBITDA of around $(105M), an improvement of $50M over 2023.

Tempus AI reported strong Q3 2024 results with revenue up 33% YoY to $180.9M. Genomics revenue grew 20.3% to $116.4M, while data and services revenue surged 64.4% to $64.5M. The company's net loss widened to $75.8M from $53.4M YoY, including $22.2M in stock compensation expenses.Tempus announced the acquisition of Ambry Genetics for $600M, comprising $375M in cash and $225M in shares. Ambry is expected to generate over $300M in revenue and $40M+ in EBITDA in 2024. The deal aims to expand Tempus' testing capabilities in hereditary cancer screening and new disease categories.For full-year 2024, Tempus maintains its revenue guidance of approximately $700M, representing 32% YoY growth. The company expects adjusted EBITDA of around $(105M), an improvement of $50M over 2023.